Zoetis Inc. ZTS SPX

Healthcare · Drug Manufacturers - Specialty & Generic · United States

https://www.zoetis.com

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Market & Price

Market Cap

$32.57B

Current Price

$77.69

High / Low (52W)

$167.69 / $74.22

Beta

0.86

Valuation

Stock P/E

12.74

Industry PE

23.65

Forward P/E

10.46

PEG Ratio

1.86

Book Value

$7.84

Price to Book

9.91

P/S

3.42

EV/EBITDA

9.79

Dividend Yield

2.73%

Profitability & Returns

ROCE

27.07%

ROE

67.75%

ROA

15.53%

Profit Margin

28.04%

Op Margin

36.56%

EPS (Latest Qtr)

$1.42

EPS (TTM)

$6.10

Balance Sheet & Liquidity

Debt/Equity

2.86

Quick Ratio

1.68

Current Ratio

3.15

Debt

$9.25B

Total Assets

$15.47B

Current Assets

$6.77B

Working Capital

$4.53B

Ownership

Promoter Holding

0.15%

Chg in Prom Hold

FII / Inst Holding

102.85%

Chg in FII Hold

0.07%

Financial Snapshot

Enterprise Value

$39.88B

Total Revenue (TTM)

$9.53B

EBITDA

$4.07B

Free Cash Flow

$1.78B

Operating Cash Flow

$2.79B

Shares Outstanding

419.23M

Gross Margin

71.84%

Payout Ratio

33.28%

Growth (CAGR)

Revenue 5Y

5.42%

Profit 5Y

8.13%

Revenue (YoY)

2.90%

Earnings (YoY)

6.00%

PROS

Strong return on equity of 67.7%.
Healthy ROCE of 27.1%.
Excellent profit margin of 28.0%.
Attractive dividend yield of 2.73%.
Generates positive free cash flow.

CONS

Trading 53.7% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ZTS Zoetis Inc. SPX	77.69	12.74	$32.57B	2.73%	27.07%	67.75%	5.42%	8.13%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Apr 2016	Jul 2016	Oct 2016	Dec 2016	Apr 2017	Jul 2017	Oct 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	1.23B	1.27B	1.35B	1.46B	1.37B	1.42B	1.48B	1.56B	1.46B	1.55B	1.58B	1.67B	1.53B	1.55B	1.79B	1.87B	1.95B	1.99B	1.99B	2.05B	2.00B	2.00B	2.18B	2.15B	2.19B	2.36B	-	-	2.20B	2.46B	2.40B	2.39B	2.26B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	618.00M	649.00M	683.00M	712.00M	641.00M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.58B	1.81B	1.72B	1.68B	1.62B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	768.00M	822.00M	781.00M	849.00M	799.00M
Operating Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	812.00M	989.00M	936.00M	826.00M	822.00M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	946.00M	1.08B	1.07B	939.00M	939.00M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	54.00M	53.00M	58.00M	57.00M	62.00M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	773.00M	902.00M	887.00M	761.00M	758.00M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	171.00M	184.00M	166.00M	158.00M	157.00M
Net Income	-37.00M	189.00M	22.00M	204.00M	224.00M	239.00M	154.00M	238.00M	247.00M	298.00M	81.00M	352.00M	384.00M	347.00M	345.00M	312.00M	371.00M	433.00M	384.00M	423.00M	377.00M	479.00M	559.00M	512.00M	552.00M	595.00M	529.00M	529.00M	552.00M	671.00M	596.00M	599.00M	624.00M	-	-	602.00M	718.00M	721.00M	603.00M	601.00M
Diluted EPS	-0.07	0.38	0.04	0.41	0.45	0.48	0.31	0.48	0.50	0.61	0.16	0.72	0.79	0.71	0.71	0.65	0.77	0.90	0.80	0.88	0.79	1.00	1.17	1.07	1.16	1.26	1.12	1.13	1.19	1.45	1.29	1.31	1.37	-	-	1.34	1.61	1.63	1.37	1.42

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	4.89B	5.31B	5.83B	6.26B	6.67B	7.78B	8.08B	8.54B	9.26B	9.47B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	2.45B	2.56B	2.72B	2.67B
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	5.63B	5.98B	6.54B	6.80B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	2.70B	2.91B	3.15B	3.20B
Operating Income	-	-	-	-	-	-	-	-	-	-	-	2.93B	3.07B	3.39B	3.60B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	3.34B	3.67B	3.85B	4.07B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	221.00M	239.00M	225.00M	222.00M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	2.66B	2.94B	3.13B	3.36B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	545.00M	596.00M	637.00M	687.00M
Net Income	245.00M	436.00M	504.00M	583.00M	339.00M	821.00M	864.00M	1.43B	1.50B	1.64B	2.04B	2.11B	2.34B	2.49B	2.67B
Diluted EPS	0.49	0.87	1.01	1.16	0.68	1.65	1.75	2.93	3.11	3.42	4.27	4.49	5.07	5.47	6.02

Compounded Sales Growth

5 Years:	5.42%
1 Year:	2.90%

Compounded Profit Growth

5 Years:	8.13%
1 Year:	6.00%

Stock Price Performance

1 Year:	-53.21%
6 Months:	-38.73%
3 Months:	-40.48%
1 Month:	-31.75%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	6.26B	6.56B	6.59B	7.91B	7.65B	8.59B	10.78B	11.54B	13.61B	-	14.93B	14.29B	14.24B	15.47B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	7.51B	6.34B	5.99B	6.77B
Cash & Equivalents	63.00M	79.00M	317.00M	610.00M	882.00M	1.15B	727.00M	1.56B	-	-	-	-	3.58B	2.04B	1.99B	2.31B
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	2.35B	2.56B	2.31B	2.43B
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	1.22B	1.30B	1.32B	1.59B
Total Liabilities	-	-	2.22B	5.60B	5.25B	6.82B	6.15B	6.80B	8.59B	8.84B	9.84B	-	10.52B	9.29B	9.47B	12.14B
Current Liabilities	-	-	1.12B	1.42B	1.09B	1.78B	1.12B	1.09B	1.22B	1.81B	2.17B	-	3.17B	1.89B	3.41B	2.23B
Long Term Debt	-	-	0	3.64B	3.62B	4.46B	4.47B	4.95B	6.44B	5.95B	6.59B	-	6.55B	6.56B	5.22B	9.04B
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	8.09B	6.75B	6.74B	9.24B
Total Equity	-	-	4.03B	940.00M	1.31B	1.07B	1.49B	1.77B	2.19B	2.71B	3.77B	-	4.41B	5.00B	4.77B	3.33B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	501.89M	501.89M	501.89M	501.89M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	497.00M	454.00M	681.00M	626.00M	664.00M	713.00M	1.35B	1.79B	1.79B	2.13B	-	1.91B	2.35B	2.95B	2.90B
Investing Cash Flow	-449.00M	-135.00M	-179.00M	-187.00M	-1.11B	-214.00M	-270.00M	-2.26B	-504.00M	-572.00M	-	-883.00M	-777.00M	-315.00M	-748.00M
Financing Cash Flow	-30.00M	-78.00M	-200.00M	-154.00M	755.00M	-903.00M	-251.00M	533.00M	-951.00M	123.00M	-	-904.00M	-3.11B	-2.66B	-1.87B
Capital Expenditure	-135.00M	-126.00M	-184.00M	-180.00M	-224.00M	-216.00M	-224.00M	-338.00M	-460.00M	-453.00M	-	-586.00M	-732.00M	-655.00M	-621.00M
Free Cash Flow	362.00M	328.00M	497.00M	446.00M	440.00M	497.00M	1.12B	1.45B	1.33B	1.67B	-	1.33B	1.62B	2.30B	2.28B
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	125.00M	-1.53B	-22.00M	286.00M
Share Buybacks	-	-	0	0	203.00M	300.00M	500.00M	698.00M	626.00M	250.00M	743.00M	1.59B	1.09B	1.86B	3.23B

Ratios (Annual)

Figures in %.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	69.6%	70.0%	70.6%	71.8%
Operating Margin %	-	-	-	-	-	-	-	-	-	-	-	36.2%	35.9%	36.6%	38.0%
Net Margin %	-	-	-	-	-	16.8%	16.3%	24.5%	24.0%	24.5%	26.2%	26.2%	27.4%	26.9%	28.2%
ROE %	-	10.8%	53.6%	44.5%	31.7%	55.2%	48.8%	65.4%	55.4%	43.5%	-	48.0%	46.9%	52.1%	80.2%
ROCE %	-	-	-	-	-	-	-	-	-	-	-	24.9%	24.8%	31.3%	27.2%

Shareholding Pattern

Insiders

0.15%

Institutions

102.85%

Public Float

103.01%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	8.49%	35.58M	$2.76B
2	Vanguard Capital Management LLC	6.22%	26.07M	$2.03B
3	Vanguard Portfolio Management LLC	5.72%	23.97M	$1.86B
4	State Street Corporation	4.61%	19.32M	$1.50B
5	State Farm Mutual Automobile Insurance Co	3.79%	15.89M	$1.23B
6	Morgan Stanley	3.37%	14.15M	$1.10B
7	Geode Capital Management, LLC	2.71%	11.35M	$881.72M
8	Wellington Management Group, LLP	2.42%	10.15M	$788.56M
9	Nordea Investment Management AB	1.40%	5.87M	$455.66M
10	Northern Trust Corporation	1.32%	5.55M	$430.87M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ZTS

No recent headlines available.

ZTS · Healthcare

Zoetis Inc.

About

Key Facts

Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Headquarters	United States
Employees	14,500
Website	https://www.zoetis.com

Press Esc or click outside to close.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Zoetis Inc. ZTS SPX

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More